<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347556">
  <stage>Registered</stage>
  <submitdate>4/10/2011</submitdate>
  <approvaldate>5/10/2011</approvaldate>
  <actrnumber>ACTRN12611001046998</actrnumber>
  <trial_identification>
    <studytitle>The Osteoarthritis Stem Cell Advanced Research Study</studytitle>
    <scientifictitle>A Randomised Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of Autologous Non-Expanded Adipose Derived Stem Cells In The Treatment Of Knee Osteoarthritis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A single 5mL injection into the knee joint space of cell suspension, which includes autologous adipose derived stem cells and sterile normal saline. On average 50million cells are injected.

Adipose (fat) tissue is removed by lipo-aspiration (this may take up to 80 minutes). The fat is processed on-site to isolate the cells (this process takes up to 2 hours). The suspension of stem cells is injected into the knee joint under ultrasound guidance. (about 20 minutes).</interventions>
    <comparator>A single 5mL injection into the knee joint space of sterile normal saline</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Outcome 1: Change in ICOAP pain scale</outcome>
      <timepoint>at 4, 12 &amp; 24 weeks after intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary Outcome 2: Percentage of patients achieving OMERACT-OARSI responder criteria.</outcome>
      <timepoint>at 4, 12 &amp; 24 weeks after intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Outcome 1: Analgesic use. A daily diary is completed by the patient to record analgesic use.</outcome>
      <timepoint>at 1, 4, 12 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Outcome 2: Change in KOOS disability scale</outcome>
      <timepoint>at 12 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Outcome 3: Australian Assessment of Quality of Life Index</outcome>
      <timepoint>at 12 and 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Aged over 40 years 
Knee pain on most days of the last month
OARSI Grade 1 or 2 with joint space narrowing in either medial or lateral compartments
or
Osteophyte grade 2 or 3 in medial or lateral compartment without Joint Space Narrowing
Symptomatic Knee Osteoarthritis as measured by a pain score of at least 42 on the Numerical Rating Scale.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Dementia or inability to give informed consent
Pregnancy or lactation
OARSI Grade 3 or above changes in either knee
Planned knee or hip joint replacement surgery
Positive blood test to HIV, HBV or HCV at Screening Visit
Positive nasal or groin swab for MRSA at Screening Visit
More than 2mm space in the knee joint on X-Ray at Screening Visit
Subjects with metal implants such as knee, hip or aortic valve prosthetics
Any clinically significant condition(s) that in the opinion of the investigator may compromise safety or compliance, interfere with evaluation or preclude completion of the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>23/02/2011</anticipatedstartdate>
    <actualstartdate>25/02/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>27/02/2012</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Regeneus Pty Ltd</primarysponsorname>
    <primarysponsoraddress>77 Ridge St Gordon NSW 2072</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Regeneus Pty Ltd</fundingname>
      <fundingaddress>77 Ridge St Gordon NSW 2072</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The trial is investigating how, and to what extent an injection of stem cells, obtained from your own fat tissue, reduces pain &amp; inflammation, repairs structural damage, affects mobility, and affects quality of life in knee osteoarthritis.</summary>
    <trialwebsite />
    <publication>No trial publications are currently available. </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hawkesbury HREC of Northern Sydney Central Coast Health</ethicname>
      <ethicaddress>Research Business Unit Level 2 Building 51, Royal North Shore Hospital Pacific Highway St Leonards NSW 2065</ethicaddress>
      <ethicapprovaldate>27/09/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Lyn March</name>
      <address>Department of Rheumatology
Royal North Shore Hospital 
Pacific Highway
St Leonards NSW 2065</address>
      <phone>+61 2 9926 7351</phone>
      <fax />
      <email>lynmar@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Tanya Fedorova</name>
      <address>Department of Rheumatology
Royal North Shore Hospital
Pacific Highway
St Leonards NSW 2065</address>
      <phone>+61 2 9926 6470</phone>
      <fax />
      <email>tanya_f@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Clinical Research Director - Janet Wilson</name>
      <address>Regeneus Pty Ltd
77 Ridge St 
Gordon NSW 2072</address>
      <phone>+61 2 9499 8010</phone>
      <fax />
      <email>humanhealth@regeneus.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lyn March</name>
      <address>Department of Rheumatology Royal North Shore Hospital Pacific Highway St Leonards NSW 2065</address>
      <phone>+61 2 9926 7351</phone>
      <fax />
      <email>lynmar@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>